Skip to main content

Table 1 Characteristics of patients with metastatic lung cancer and with management of chemotherapy in the public sector and access to FICHCOMP drugs: univariate and multivariate logistic regression analysis (multi-level analysis)

From: Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

  All patients (N = 11,486) Patients with FICHCOMP drug use (N = 6959) Univariate analysis Multivariate analysis
n (% col)a n (% row)b OR [95% CI] OR [95% CI]
Age at inclusion (years)
  ≤ 55 yrs 2923 (25.4%) 2058 (70.4%) 1.00 1.00
 56–65 yrs 4206 (36.6%) 2659 (63.2%) 0.72 [0.65–0.80] 0.76 [0.69–0.84]
  ≥ 66 yrs 4357 (37.9%) 2242 (51.5%) 0.44 [0.40–0.49] 0.49 [0.44–0.55]
Gender
 Men 8172 (71.1%) 4819 (59.0%) 0.79 [0.72–0.86] 0.86 [0.79–0.94]
 Women 3314 (28.9%) 2140 (64.6%) 1.00 1.00
Comorbidities
 Hypertension 2584 (22.5%) 1370 (53.0%) 0.68 [0.62–0.74] 0.88 [0.80–0.97]
 Diabetes 1151 (10.0%) 567 (49.3%) 0.61 [0.54–0.69] 0.79 [0.69–0.90]
 Renal insufficiency 224 (2.0%) 87 (38.8%) 0.41 [0.31–0.54] 0.55 [0.41–0.73]
 COPD 1506 (13.1%) 744 (49.4%) 0.60 [0.54–0.67] 0.71 [0.63–0.80]
 Pulmonary insufficiency 461 (4.0%) 225 (48.8%) 0.60 [0.50–0.73] 0.73 [0.60–0.88]
 Other chronic lung diseases 855 (7.4%) 444 (51.9%) 0.68 [0.59–0.78] 0.93 [0.79–1.08]
Type of hospital for first stay with chemotherapyc
 CH 5615 (48.9%) 3405 (60.6%) 1.00
 CHU 3284 (28.6%) 2019 (61.5%) 1.03 [0.95–1.13]
 CLCC 1193 (10.4%) 716 (60.0%) 0.93 [0.81–1.06]
 Others 1394 (12.1%) 819 (58.8%) 0.91 [0.80–1.03]
Population density of municipality (quartile; population nb hab/km2)c
 Very low density (≤ 86) 2891 (25.2%) 1693 (58.6%) 0.94 [0.83–1.06]
 Low density (]86–309]) 2905 (25.3%) 1743 (60.0%) 1.02 [0.91–1.15]
 High density (]309–2073]) 2872 (25.0%) 1772 (61.7%) 1.07 [0.95–1.21]
 Very high density (> 2073) 2818 (24.5%) 1751 (62.1%) 1.00
Social deprivation of municipality (quartile)
 Most deprived 3031 (26.4%) 1762 (58.1%) 0.82 [0.73–0.93] 0.82 [0.72–0.92]
 Deprived 3249 (28.3%) 1958 (60.3%) 0.90 [0.80–1.01] 0.87 [0.78–0.98]
 Privileged 2461 (21.4%) 1493 (60.7%) 0.93 [0.82–1.04] 0.90 [0.80–1.02]
 Most privileged 2745 (23.9%) 1746 (63.6%) 1.00 1.00
  1. COPD chronic obstructive respiratory disease, CH community hospital, CHU university hospital, CLCC cancer care clinic, OR odds ratio, 95%CI 95% confidence interval
  2. aPercentage calculated with total number of patients as the denominator (11486). bPercentage calculated as number of patients in class receiving FICHCOMP drugs. cNon-significant variable in the univariate analysis (threshold = 10%), therefore not included in the multivariate analysis